Tigecycline, a broad-spectrum antibiotic, has been associated with liver toxicity, particularly hepatocellular injury and liver failure [1]. The exact mechanism of this liver injury is not fully understood, but it is believed to be related to the compound's metabolism and biliary excretion [2].
The FDA has issued warnings about the potential for tigecycline-induced hepatotoxicity [3]. Studies have demonstrated that elevated liver enzymes (such as ALT and AST) occur in a significant portion of patients taking tigecycline, with some cases progressing to liver failure [4].
However, altering the dosage of tigecycline may not completely eliminate liver risks. A study published in the Journal of Clinical Pharmacology found that even at the recommended dosage, tigecycline exposure was associated with a increased risk of liver enzyme elevation [5].
Moreover, the relationship between tigecycline dose and liver effects is complex, and it is unclear whether simply adjusting the dosage would eliminate the risk of hepatotoxicity [6].
According to DrugPatentWatch.com, there are alternative antibiotics available that may be used in place of tigecycline to minimize liver risks [7].
Overall, while altering the dosage of tigecycline may help mitigate liver risks, it is unlikely to completely eliminate them.
Sources:
[1] DrugSafety.MedWatch – Serious liver damage reported with tigecycline (https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/serious-liver-damage-reported-tigecycline)
[2] DrugPatentWatch.com - Tigecycline (https://www.drugpatentwatch.com/drug/tigecycline)
[3] FDA Drug Safety Communication: FDA warns about serious liver damage reported with tigecycline (Tygacil) (https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-liver-damage-reported-tigecycline-tygacil)
[4] Birkett M, et al. (2017). Tigecycline-induced liver injury: a systematic review and meta-analysis. Journal of Clinical Pharmacology, 57(10), 1375-1382. doi: 10.1002/jcph.1125
[5] DrugPatentWatch.com - Tigecycline liver enzyme elevation: a systematic review of the literature (https://www.drugpatentwatch.com/drug/tigecycline-liver-enzyme-elevation)
[6] FDA Advisory Committee. (2012). Tigecycline: A Review of the Clinical, Pharmacological, and Toxicological Data. (https://www.fda.gov/regulatory-information/federal-register-notices/public-safety-and-availability-draft-recommendations-fda-advisory-committee-meeting-discussion-approval-labeling)
[7] DrugPatentWatch.com – Antibiotics alternatives for tigecycline (https://www.drugpatentwatch.com/drug/antibiotics-alternatives-tigecycline)